Blueprint Medicines (NASDAQ: BPMC) reported Q4 EPS of ($1.53), $0.09 better than the analyst estimate of ($1.62). Revenue for the quarter came in at $34.1 million versus the consensus estimate of $29.24 million.

For earnings history and earnings-related data on Blueprint Medicines (BPMC) click here.